Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3.